Aphton Corp - Turn Around Chance? - 500 Beiträge pro Seite

[ProMaiLer]

Eins vorweg, ich würde den Wert nicht kaufen!

Aphton Corp - APHT

Aktueller Kurs: 0,97 $
MK 58 Mio $
Institutionelle: 33%, wobei Instititionelle weiter aufgestockt haben, was doch verwunderlich erscheint

Gewinn/Verlust in Mio:
01:- 28,762 $
02:- 26,300 $
03:- 39,990 $
04:- 31,264 $
05 Q1: -60,8 $

Umsätze werden noch nicht gemacht!






Aphton Corporation, headquartered in Philadelphia, Pennsylvania is a clinical stage biopharmaceutical company focused on developing targeted immunotherapies for cancer. Aphton`s products seek to empower the body`s own immune system to fight disease. Through the acquisition of Igeneon AG in March 2005, Aphton acquired late-stage products, IGN101, a cancer vaccine designed to induce an immune response against EpCAM positive tumor cells, and IGN311, a fully humanized antibody against the Lewis Y antigen. Aphton is currently seeking partners that will support the further development of Insegia (G17DT immunogen), its immunogen targeting the hormone gastrin. Aphton has strategic alliances with sanofi-aventis for the development and commercialization of Insegia related to cancers of the gastrointestinal system and other cancers in North America and Europe ; Daiichi Pure Chemicals for the development, manufacturing and commercialization of gastrin-related diagnostic kits; and Xoma for developing humanized monoclonal and other antibodies to treat gastrointestinal and other gastrin-sensitive cancers.

[asics01]

hallo
gehen da bald die lichter aus,oder kann man ein spielchen wagen ???
asics

[pwcalex]

Hallo zusammen,
bin ganz neu in Foren.
Habe Aphton auch gekauft. Sehe tatsächlich Turnaround, da Aphton auch weiterhin den Kapitalmarkt braucht.
Denke das Board wird den Kurs bis zum 25.11. pushen müssen.
Wie seht Ihr die Lage?

[pwcalex]

gar keiner da der mitjaubeld?
aphton steigt bis auf 1€ diese woche!
juhuu....

[asics01]

aphton geht heute ganz ab,riesige umsätze was ist los ??
asics

[asics01]

was war das gestern für eine veranstaltung zuerst hochgezockt auf 0,45 und dann auf eröffnungskurs 0.30 geschlossen ??

[cyberhai]

Bin eingestiegen, ist sonst noch jemand investiert?

Sobald nur ein Funke einer positven Nachricht kommt, dürften wir hier eine kleine Explosion erleben Oder es gibt eine Pleite

Gruß Cyberhai

[asics01]

hallo cyberhai
aphton schmiert in usa gerade ab habe eine kauforder in usa bei 0.19 rausgehauen.bin auch dabei
asics

[asics01]

bin leider doch nicht dabei meine kauforder wurde gestrichen, wollte dann nochmal ordern auch die 2te wurde gestrichen wieso??bin bei consors
asics

[cyberhai]

Hallo!

Ich kann mir das auch nicht erklären. Bin bei codi und da geht das mit der limitierten Order gut. 0.19 wäre sicher ein guter Einstieg gewesen - ich ärgere mich wieder mal über den zu frühen Einstieg...

Gruss cyberhai

[cyberhai]

Hier der Grund für den Absturz am Donnerstag, am Freitag wurde Zahlen veröffentlicht:

http://finance.yahoo.com/q/is?s=apht

Gruß Cyberhai

[cyberhai]

31-Jan-2006

Notice of Delisting or Transfer

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On January 27, 2006, the Company received notice from The Nasdaq Stock Market informing the Company that the NASDAQ Listing Qualifications Panel had determined to delist the Company`s securities from The Nasdaq Stock Market, effective with the open of business on January 31, 2006. The Panel`s decision to delist was based upon the Company`s failure to comply with NASDAQ Marketplace Rule 4310(c)(ii)(B), which requires the Company to maintain a market value of listed securities of at least $35,000,000 or, in the alternative, shareholders` equity of at least $2,500,000 and the Company`s failure to evidence a minimum bid price of $1.00 per share, as required by NASDAQ Marketplace Rule 4310(c)(4). The notice from NASDAQ follows the Company`s announcement on November 29, 2005 that the Company would request a hearing before the NASDAQ Listing Qualifications Panel to review the NASDAQ Listing Qualifications Staff Determination to delist the Company`s securities and to seek continued listing on The Nasdaq Capital Market. The hearing was held on December 22, 2005.

Today, the Company filed a formal request with the NASDAQ Listing Qualifications Panel for reconsideration of the determination to delist the Company`s securities. The request is based upon certain mistakes of material fact contained in the Panel decision and was filed in accordance with NASDAQ Marketplace Rule 4808(a). The request for reconsideration will not stay the delisting action referenced in the Panel`s January 27, 2006 letter. As such, the Company`s securities will be delisted from The Nasdaq Stock Market effective with the open of business on Tuesday, January 31, 2006. The Panel has indicated that it will rule on the request for reconsideration on or before February 14, 2006. There can be no assurance that the Panel will grant the Company`s request for re-listing on The Nasdaq Stock Market.

The Company expects its shares to immediately begin trading in the "pink sheets" under the ticker symbol APHT effective with the open of business on January 31, 2006. The Company`s common stock may, in the future, also be quoted on the Over-the-Counter Bulletin Board maintained by the NASD, provided that a market maker in the common stock files the appropriate application with, and such application is cleared by, the NASD. The Company anticipates disclosing further trading venue information for its common stock once such information becomes available.

[cyberhai]

Aphton to Expand Licensing and Commercialization Agreements into Europe for IGN311
Tuesday February 7, 10:26 am ET
Agreement to Include Substantial Amount of Contribution with the Potential of at Least $40 Million Value in Cash, Milestones, and Development Costs, Including $5 Million up Front Payment

PHILADELPHIA--(BUSINESS WIRE)--Feb. 7, 2006--Aphton Corporation (Pink Sheets:APHT - News) announced today that its wholly-owned subsidiary, Igeneon, signed a letter of intent with Celltrion to amend their existing licensing and commercialization agreements for the clinical product candidate, IGN311, a humanized monoclonal antibody against the Lewis-Y carbohydrate antigen and Igeneon`s next-generation antibody, IGN312.

Under the original agreements, which closed in November 2005, Igeneon granted Celltrion an exclusive license to commercialize IGN311 in certain Asian countries, including Japan, in exchange for future milestone payments and royalties from Celltrion. In addition, under the original agreements, Celltrion will provide development and manufacturing services related to the optimization and upscaling of IGN311 as well as material for further clinical development.

Under the terms of the letter of intent, Igeneon would expand the existing license to permit Celltrion to commercialize IGN311 in Europe as well as grant Celltrion an additional license to commercialize Igeneon`s next-generation antibody, IGN312, in Europe and certain countries in Asia, including Japan. In addition, for a period of time to be determined, Celltrion would have a right of first refusal to further develop and commercialize IGN101, which is Igeneon`s cancer vaccine that is currently in a 760 patient Phase II/III clinical trial. In return, Igeneon would receive from Celltrion an up front payment of $5 million and milestone payments of up to $15 million. In addition, Igeneon would receive royalties on sales of each product in both territories and Celltrion would assume all clinical development costs for IGN311 in both territories. The companies intend to initiate Phase I and Phase II clinical trials of IGN311 in Asia in the near future.

The signing of the definitive agreement is pending approval of the Boards of Directors of both Aphton and Celltrion.

"We believe the expansion into Europe of our existing collaboration with Celltrion is validation of both the IGN311 and IGN312 franchises," commented Patrick Mooney, MD, President and Chief Executive Officer of Aphton. "By committing to pay up to $20 million in up front and milestone payments, plus assuming all development costs of IGN311 in Europe and Asia, we believe that Celltrion is making a significant statement about its belief in the potential of these products. In addition, Aphton would retain the rights to the products in North and South America and the rest of the world, which, based on the current terms of this expansion, would provide us with a tremendous opportunity in the future."

About IGN311 and IGN312

IGN311 is a humanized monoclonal antibody against the Lewis Y carbohydrate antigen, a blood-group-related oligosaccharide. Lewis Y is over-expressed in up to 90% of all epithelial cancers and its expression on adult normal tissues is very restricted; hence IGN311 has the potential to target a broad range of carcinomas. IGN311 is designed to exert clinical effects by destruction of tumor cells by activation of effector functions and by selective growth inhibition via functional receptors. IGN312 is a next-generation antibody based on IGN311.

[cyberhai]

BioWa and Aphton Announce Licensing of BioWa`s POTELLIGENT(TM) Technology
Tuesday February 14, 8:00 am ET
Aphton to Use BioWa`s POTELLIGENT(TM) Antibody Technology for Development of Preclinical IGN312 Anti-Lewis Y antibody

PRINCETON, N.J. & PHILADELPHIA, Pa.--(BUSINESS WIRE)--Feb. 14, 2006--BioWa, Inc. and Aphton Corporation (Pink Sheets:APHT - News) today announced that BioWa has granted a non-exclusive license to Apthon`s wholly-owned subsidiary, Igeneon, to use BioWa`s POTELLIGENT(TM) technology for the development of IGN312, a humanized monoclonal Lewis Y-specific antibody. Aphton, through Igeneon, develops IGN312 as a next-generation antibody based on IGN311, which is currently in a Phase I/II clinical trial in patients with Lewis Y-positive cancers.

Aphton plans to use BioWa`s POTELLIGENT technology for the development of a next-generation Lewis Y-specific antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC). Lewis Y is a tumor-related antigen expressed in up to 90% of all epithelial cancers, which include breast, colon, gastric and pancreatic cancers. BioWa`s POTELLIGENT technology has the potential to increase the ADCC activity of an antibody, resulting in greater capacity to destroy tumor cells.

"We are very pleased to be working with an innovative cancer immunotherapy company like Igeneon, who has successfully progressed its antibody program to the clinical stage," said Nobuo Hanai, Ph.D., President and CEO of BioWa, Inc. "This licensing agreement enforces BioWa`s strategy to bring about more effective and safe treatments for cancer."

"We look forward to the rapid application of the POTELLIGENT technology, which has the potential to effectively increase the potency of IGN312 as an anti-cancer treatment," said Patrick Mooney, MD, Chairman and CEO of Aphton Corporation. "Entering into this partnership with BioWa is an important step in our efforts to continue to develop promising product candidates to fuel our clinical pipeline in the future."

This agreement was mediated by FHR Consult (http://www.fhrconsult.com) on behalf of BioWa.

About IGN311 and IGN312

IGN311 is a humanized monoclonal antibody against the Lewis Y carbohydrate antigen, a blood-group-related oligosaccharide. Lewis Y is over-expressed in up to 90% of all epithelial cancers and its expression on adult normal tissues is very restricted; hence IGN311 has the potential to target a broad range of carcinomas. IGN311 is designed to exert clinical effects by destruction of tumor cells by activation of effector functions and by selective growth inhibition via functional receptors. IGN312 is a next-generation antibody based on IGN311.

[lotte123]

warum wird nicht mehr an der nasdaq gehandelt?

[cyberhai]

Haben die Kriterien nicht mehr erfüllt wie Mindestkurs von 1 Dollar und einer Marktkapitalisierung von mind. 35 Mio bzw. mit Zustimmung der Aktionäre von 2,5 Mio Dollar.

Die Aktie hat sich vom Tief bereits wieder um mehr als 50 % erholt.

Der Nachrichtenfluss ist in letzter Zeit auch wieder positiv, sollte noch eine gute Meldung wegen der Phase III-Studie kommen, kann die Rakete starten.

Gruß Cyberhai

[nort.]

* Lesezeichen *

[asics01]

bin heute bei 0,12€ rein .